financetom
Business
financetom
/
Business
/
Mexico's presidential front-runner aims to cut oil refinery waste, advisor says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mexico's presidential front-runner aims to cut oil refinery waste, advisor says
Apr 4, 2024 2:39 PM

MEXICO CITY, April 4 (Reuters) - Mexico's presidential

front-runner Claudia Sheinbaum plans to invest in state-owned

Pemex' oil refineries to reduce the huge volumes of low-value

fuels produced and instead boost the output of motor fuels, one

of her advisors said.

Pemex has been producing record levels of heavy fuels, such

as the particularly polluting fuel oil, as its local refineries

struggle to process the heavy Maya crude it pumps.

Last year, Pemex produced 260,285 barrels per day (bpd) of

fuel oil - exceeding the production of gasoline at 252,203 bpd.

Considered a waste product, in Mexico fuel oil is mainly

burnt for electricity generation.

"Refineries are very expensive and important assets to reach

energy self-sufficiency," said Jorge Islas, the energy

coordinator for Sheinbaum, in an interview on Wednesday.

Islas, a physicist and doctor in economics, pointed to the

possibility of building a new coking unit at the Salamanca

refinery to increase gasoline and diesel production. Currently,

the refinery is operating at just over half of its capacity.

Coking units are able to process the heavier hydrocarbons

coming out of distillation towers into higher-value products,

including motor fuels.

Under President Andres Manuel Lopez Obrador, Pemex has

invested billions of dollars to rehabilitate its six obsolete

domestic refineries. Refining has been a loss-making business

for Pemex for years.

In order to wean the country off expensive imports, Pemex

also formally inaugurated the new Dos Bocas refinery in July

2022, despite running late and over budget by several billions

of dollars. While the 340,000-bpd refinery is operational, it

does not yet produce finished fuels.

Pemex already has two new coking plants in Salamanca and

Tula which are expected to come into operation between this year

and next.

Lopez Obrador had promised that Mexico would achieve

"energy sovereignty" during his six-year term. However, a few

months before he leaves office on Oct. 1, the goals seem complex

to achieve even as refineries have improved their performance.

The six local refineries together have the capacity to

process 1.6 million bpd. However, in the first two months of

this year, they processed an average of 945,000 bpd - above the

612,000 bpd in 2018 they processed before Lopez Obrador took

office but still well below capacity.

With the Dos Bocas refinery set to fully operate this year,

and Pemex also wanting more crude for its other refineries, it

has asked its commercial unit TRI to cut crude exports this

month by 436,000 bpd.

The government plans to continue reducing its exports, which

amounted to 945,000 bpd in the first two months of this year.

Islas reiterated that according to Sheinbaum's plan,

production would be at around 1.8 million bpd of crude oil and

condensate even after there have been few large discoveries of

reserves.

"Smaller reserves are being discovered each time, at greater

depth, with higher costs," said Islas.

"What is being thought about is the energy transition from

fossils to renewables," he said. "Maintain a fixed hydrocarbon

production platform, make better use of the energy and cover the

new demand with renewable energy."

Asked about the finances of the highly indebted Pemex, Islas

said that a Sheinbaum government would look for "aid schemes"

and "better options".

"But support can't be eternal and the company must improve,

show it can be accountable," he said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Facebook owner Meta restarts facial recognition tech in 'celeb-bait' crackdown
Facebook owner Meta restarts facial recognition tech in 'celeb-bait' crackdown
Oct 22, 2024
SYDNEY/NEW YORK (Reuters) - Three years after Meta shut down facial recognition software on Facebook amid a groundswell of privacy and regulator pushback, the social media giant said on Tuesday it is testing the service again as part of a crackdown on celeb bait scams. Meta said it will enroll about 50,000 public figures in a trial which involves automatically comparing...
Td Synnex Insider Sold Shares Worth $2,462,800, According to a Recent SEC Filing
Td Synnex Insider Sold Shares Worth $2,462,800, According to a Recent SEC Filing
Oct 22, 2024
06:00 PM EDT, 10/21/2024 (MT Newswires) -- David R Vetter, Chief Legal Officer, on October 18, 2024, sold 20,000 shares in Td Synnex ( SNX ) for $2,462,800. Following the Form 4 filing with the SEC, Vetter has control over a total of 66,381 shares of the company, with 66,381 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1177394/000112760224025811/xslF345X05/form4.xml ...
BRIEF-Axis Enters Into Asset Purchase Agreement For Sale Of Auto Finance Business
BRIEF-Axis Enters Into Asset Purchase Agreement For Sale Of Auto Finance Business
Oct 22, 2024
Oct 21 (Reuters) - Axis Auto Finance Inc: * AXIS ENTERS INTO ASSET PURCHASE AGREEMENT FOR SALE OF AUTO FINANCE BUSINESS * BASE PURCHASE PRICE FOR ASSETS APPROXIMATELY $114 MILLION * ENTERS INTO ASSET PURCHASE AGREEMENT WITH FIONIC CANADA * COMMON SHARES EXPECTED TO BE DELISTED FROM TORONTO STOCK EXCHANGE AFTER CLOSING Source text for Eikon: Further company coverage: ...
Editas Medicine, Genevant Partner to Develop mRNA-LNP Gene Editing Therapeutics
Editas Medicine, Genevant Partner to Develop mRNA-LNP Gene Editing Therapeutics
Oct 22, 2024
06:05 PM EDT, 10/21/2024 (MT Newswires) -- Editas Medicine ( EDIT ) and Genevant Sciences said Monday they will combine Editas' CRISPR Cas12a genome editing systems with Genevant's LNP technology in the development of in vivo gene editing medicines for two targets in Editas' upregulation strategy. Genevant granted Editas a nonexclusive license to exploit mRNA-CRISPR Cas12a-LNP products for the targets,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved